CALT

CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders

Retrieved on: 
Dienstag, Mai 28, 2024
Class Action Lawsuit, Professional Services, Legal, Asahi Kasei, Sale, Advertising, CALT, Fraud

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Calliditas Therapeutics AB (NASDAQ: CALT) to Asahi Kasei Corporation for SEK 416 in cash per American Depositary Share is fair to Calliditas shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Calliditas Therapeutics AB (NASDAQ: CALT) to Asahi Kasei Corporation for SEK 416 in cash per American Depositary Share is fair to Calliditas shareholders.
  • On behalf of Calliditas shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Neuhaus Education Center Appoints New Chief Academic Officer

Retrieved on: 
Dienstag, Mai 21, 2024
Preschool, Other Philanthropy, Other Education, University, Philanthropy, Primary, Secondary, Education, Training, Instructional design, Professional development, Science, Translation, Family support, Research, Safety, CALT, International Dyslexia Association, Student, Dyslexia, Multimedia, Tutoring

Neuhaus Education Center, a non-profit organization committed to promoting reading success for all, proudly announces the promotion of Dr. Catherine Hungerford Scott, CALT, Reading Specialist, to Chief Academic Officer, effective May 8.

Key Points: 
  • Neuhaus Education Center, a non-profit organization committed to promoting reading success for all, proudly announces the promotion of Dr. Catherine Hungerford Scott, CALT, Reading Specialist, to Chief Academic Officer, effective May 8.
  • View the full release here: https://www.businesswire.com/news/home/20240521813214/en/
    Dr. Tracy White Weeden, President and CEO of Neuhaus Education Center, stated, “Dr.
  • Dr. Scott's commitment to Neuhaus began in 2003 when she took her first class at Neuhaus Education Center as a classroom teacher.
  • “I am so grateful to have the opportunity to be part of Neuhaus Education Center.

Calliditas Therapeutics' 2023 Annual Report Published

Retrieved on: 
Mittwoch, April 24, 2024
Sustainability, Annual report, CALT, Person

STOCKHOLM, April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available at the company's website: www.calliditas.com

Key Points: 
  • STOCKHOLM, April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available at the company's website: www.calliditas.com
    Åsa Hillsten, Head of IR & Sustainability, Calliditas
    Tel.
  • : +46 76 403 35 43, Email: [email protected]
    This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act.
  • The information was sent for publication, through the agency of the contact persons set out above, on April 24, 2024, at 7:00 p.m. CET.

Calliditas Therapeutics' 2023 Annual Report Published

Retrieved on: 
Mittwoch, April 24, 2024
Sustainability, Annual report, CALT, Person

STOCKHOLM, April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available at the company's website: www.calliditas.com

Key Points: 
  • STOCKHOLM, April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available at the company's website: www.calliditas.com
    Åsa Hillsten, Head of IR & Sustainability, Calliditas
    Tel.
  • : +46 76 403 35 43, Email: [email protected]
    This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act.
  • The information was sent for publication, through the agency of the contact persons set out above, on April 24, 2024, at 7:00 p.m. CET.

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Retrieved on: 
Donnerstag, April 18, 2024
Congress, CALT, UPCR, Immunoglobulin A, EGFR, Patient, Budesonide, ISN, Pharmaceutical industry

STOCKHOLM, April 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.

Key Points: 
  • STOCKHOLM, April 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.
  • "We were pleased to share additional analyses from the 2-year Phase 3 NeflgArd trial of Nefecon in IgAN at this year's World Congress of Nephrology," said Richard Philipson, Chief Medical Officer of Calliditas.
  • "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."
  • These findings strongly suggest preserved kidney function and provide support for Nefecon as a disease-modifying therapy in patients with IgAN.

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Retrieved on: 
Donnerstag, April 18, 2024
Congress, CALT, UPCR, Immunoglobulin A, EGFR, Patient, Budesonide, ISN, Pharmaceutical industry

STOCKHOLM, April 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.

Key Points: 
  • STOCKHOLM, April 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.
  • "We were pleased to share additional analyses from the 2-year Phase 3 NeflgArd trial of Nefecon in IgAN at this year's World Congress of Nephrology," said Richard Philipson, Chief Medical Officer of Calliditas.
  • "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."
  • These findings strongly suggest preserved kidney function and provide support for Nefecon as a disease-modifying therapy in patients with IgAN.

Calliditas Therapeutics to Attend Conferences in April

Retrieved on: 
Dienstag, April 9, 2024
Congress, Conference, CALT, Future, Sustainability, LSX, Inflation, Pharma, Person, Pharmaceutical industry

STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:

Key Points: 
  • STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:
    Van Lanschot Kempen Life Sciences Conference Amsterdam, Tuesday, April 16, 2024.
  • Renée Aguiar-Lucander, CEO, will be available for one-on-one meetings.
  • World Orphan Drug Congress, Thursday, April 25, 2024, in Boston, MA.
  • Maria Törnsén, President North America, will be moderating a panel, entitled "Partnering in the rare disease space - industry perspective".

Calliditas Therapeutics to Attend Conferences in April

Retrieved on: 
Dienstag, April 9, 2024
Congress, Conference, CALT, Future, Sustainability, LSX, Inflation, Pharma, Person, Pharmaceutical industry

STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:

Key Points: 
  • STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:
    Van Lanschot Kempen Life Sciences Conference Amsterdam, Tuesday, April 16, 2024.
  • Renée Aguiar-Lucander, CEO, will be available for one-on-one meetings.
  • World Orphan Drug Congress, Thursday, April 25, 2024, in Boston, MA.
  • Maria Törnsén, President North America, will be moderating a panel, entitled "Partnering in the rare disease space - industry perspective".

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Montag, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Montag, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.